AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2011
Jun 27, 2011
35334_dirs_2011-06-27_831afbfd-48e0-4c8a-b7b5-4dfd3f79ded6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2011-06-24
Reporting Person: Equels Thomas K. (General Counsel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-06-24 | Options to buy Common Stock | $0.41 | J | 300000 | Acquired | 2021-06-24 | Common Stock (300000) | Direct |
More from AIM ImmunoTech Inc.
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 14